Categories Earnings, Other Industries
Earnings Summary: Highlights of Johnson Controls (JCI) Q4 2024 results
Johnson Controls International plc (NYSE: JCI), a sustainable building solutions provider, announced results for the fourth quarter and fiscal 2024. It also provided guidance for the first quarter.
- Fourth-quarter sales increased 7% year-over-year to $6.25 billion and grew 10% organically
- Adjusted profit increased to $1.28 per share in the September quarter from $1.05 per share in Q4 2023
- Net income attributable to the company was $633 million in the first quarter, vs. $549 million last year
- On a per-share basis, Q3 earnings rose to $0.95 per share from $0.80 per share in the year-ago quarter
- Fourth-quarter orders increased 8% organically year-over-year; the building Solutions backlog was $13.1 billion, up 7% organically
- For the first quarter of fiscal 2025, the management expects organic sales growth of mid-single digits
- Adjusted segment EBITA margin is expected to be ~14.5% in Q1; the guidance for adjusted EPS before special items is $0.57-$0.60 for the first quarter
Listen to the conference calls as they happen. Don't miss a beat! With AlphaStreet Intelligence, you can listen to live calls and interviews as they happen, so you never have to worry about missing out on important information.
Most Popular
DIS Earnings: All you need to know about Walt Disney’s Q4 2025 earnings results
The Walt Disney Company (NYSE: DIS) reported its fourth quarter 2025 earnings results today. Revenues of $22.5 billion were comparable to the year-ago quarter. Net income attributable to The Walt
Cisco (CSCO) reports higher Q1 revenue and earnings; results beat estimates
Network gear maker Cisco Systems Inc. (NASDAQ: CSCO) on Wednesday announced financial results for the first quarter of fiscal 2026, reporting higher revenue and profit. Earnings, on an adjusted basis,
Advantage of CERo’s CER receptor lies in native human protein-based antigen binding: CEO
CERo Therapeutics Holdings, Inc. is a biotechnology company pioneering engineered T cell immunotherapies to combat cancer, with a focus on hematologic malignancies and solid tumors. In an email conversation with
